IDEAYA Biosciences (IDYA) Income from Continuing Operations (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Income from Continuing Operations of 232765000.0 for Q1 2026, down 147.48% sequentially from 94055000.0 in Q4 2025, and down 149.92% YoY from 466280967.89 in Q1 2025.
IDEAYA Biosciences (IDYA) Income from Continuing Operations (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Income from Continuing Operations for 9 years, with the latest figure at 232765000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 149.92% year-over-year to 232765000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 432089000.0 (up 19.4% YoY) and the FY2025 annual result came in at 354263000.0, up 27.94% from the prior year.
- Income from Continuing Operations slipped to 232765000.0 in Q1 2026 per IDYA's latest filing, from 94055000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 30153000.0 in Q3 2025 and troughed at 232765000.0 in Q1 2026.
- A 5-year average of 74201941.18 and a median of 39174000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 379.35% in 2024, then soared 122.45% in 2025.
- Over 5 years, Income from Continuing Operations stood at 25326000.0 in 2022, then tumbled by 54.68% to 39174000.0 in 2023, then tumbled by 275.66% to 147162000.0 in 2024, then surged by 36.09% to 94055000.0 in 2025, then sank by 147.48% to 232765000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 232765000.0, 94055000.0, and 30153000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | -289.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -289.48 Mn |
| Mar 31, 2026 | -232.77 Mn |
| Dec 31, 2025 | -94.06 Mn |
| Sep 30, 2025 | 30.15 Mn |
| Jun 30, 2025 | -135.42 Mn |
| Mar 31, 2025 | -93.14 Mn |
| Dec 31, 2024 | -147.16 Mn |
| Sep 30, 2024 | -134.32 Mn |
| Jun 30, 2024 | -161.44 Mn |
| Mar 31, 2024 | -53.54 Mn |
| Dec 31, 2023 | -39.17 Mn |
| Sep 30, 2023 | -33.87 Mn |
| Jun 30, 2023 | -33.68 Mn |
| Mar 31, 2023 | -26.28 Mn |
| Dec 31, 2022 | -25.33 Mn |
| Sep 30, 2022 | -18.18 Mn |
| Jun 30, 2022 | -37.92 Mn |
| Mar 31, 2022 | -25.31 Mn |
| Dec 31, 2021 | -20.88 Mn |
| Sep 30, 2021 | -11.83 Mn |